What's Happening?
SBH Sciences, a preclinical contract research organization based in Natick, MA, has launched a Translational Kidney Disease Platform to aid in the development of renal therapeutics. The platform addresses challenges in drug development for chronic kidney
disease (CKD) by integrating human-relevant in vitro models and biomarker strategies. It utilizes compartment-specific kidney cell systems and extracellular vesicle-based assays to align preclinical findings with clinical outcomes. SBH Sciences, with over 28 years of experience, has supported numerous biotechnology and pharmaceutical companies, contributing to the advancement of several New Chemical Entities into clinical trials.
Why It's Important?
Chronic kidney disease affects over 800 million people globally, posing significant health challenges. The new platform by SBH Sciences aims to improve the predictability and effectiveness of preclinical models, which are crucial for developing new treatments. By providing a more accurate representation of human kidney biology, the platform could accelerate the development of therapies for CKD and related conditions. This advancement holds potential benefits for patients, healthcare providers, and pharmaceutical companies by enhancing drug discovery and reducing the time and cost associated with bringing new treatments to market.
What's Next?
SBH Sciences plans to collaborate with biotechnology and pharmaceutical organizations to further develop therapies for CKD and other renal conditions. The platform's integration of cellular systems and biomarker endpoints is expected to enhance decision-making in drug development processes. Future research may focus on refining these models and expanding their application to other diseases. The success of this platform could lead to broader adoption of similar translational approaches in other areas of drug development, potentially transforming the landscape of therapeutic innovation.
